Peter G. Schultz
Founder chez Wildcat Discovery Technologies, Inc.
Profil
Peter G.
Schultz is the founder of Symyx Technologies, Inc. (1996), Achaogen, Inc. (2002), Ambrx, Inc. (2003), Ardelyx, Inc. (2007), and Wildcat Discovery Technologies, Inc. (2006).
He is also the founder of Phenomix Corp., Syrrx, Inc., Kalypsys, Inc. Dr. Schultz's current jobs include Scientist at Affymax Research Institute, and Professor at The Scripps Research Institute.
He is also a Member of the National Academy of Sciences (since 1993) and the National Academy of Medicine (since 1998).
Dr. Schultz's former jobs include Director at Nanosphere, Inc. and The Assay Depot, Inc., Institute Director at Novartis Institute for Functional Genomics, Inc. (1999-2010), Director at Synchronicity Pharma, Inc., Investigator at Howard Hughes Medical Institute, Inc., Professor at the University of California, Berkeley (1985-1998), and Advisor at Presidio Partners.
Dr. Schultz received his doctorate degree from the California Institute of Technology in 1984 and his undergraduate degree from the same institution in 1979.
Postes actifs de Peter G. Schultz
| Sociétés | Poste | Début |
|---|---|---|
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Corporate Officer/Principal | - |
Wildcat Discovery Technologies, Inc.
 Wildcat Discovery Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA. | Founder | 01/01/2006 |
National Academy of Sciences
 National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Corporate Officer/Principal | 23/07/2009 |
National Academy of Medicine (United States)
 National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Corporate Officer/Principal | 23/07/2009 |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | - |
Anciens postes connus de Peter G. Schultz
| Sociétés | Poste | Fin |
|---|---|---|
| ARDELYX, INC. | Founder | 10/12/2015 |
| AMBRX INC | Founder | 12/12/2013 |
Symyx Technologies, Inc.
 Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Founder | 19/07/2011 |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Founder | 28/10/2010 |
| ░░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Peter G. Schultz
| California Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARDELYX, INC. | Health Technology |
| Entreprise privées | 17 |
|---|---|
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Syrrx, Inc.
 Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Nanosphere, Inc.
 Nanosphere, Inc. Medical SpecialtiesHealth Technology Nanosphere, Inc. engages in the development, manufacture, and market of molecular diagnostics platform. Its platform, Verigene System, enables clinicians to identify and treat bacteria and viruses responsible for some of the most complex, costly, and deadly infectious diseases. The company was founded by Chad A. Mirkin and Robert Letsinger on December 30, 1999 and is headquartered in Northbrook, IL. | Health Technology |
Wildcat Discovery Technologies, Inc.
Wildcat Discovery Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA. | Commercial Services |
The Assay Depot, Inc.
 The Assay Depot, Inc. Miscellaneous Commercial ServicesCommercial Services The Assay Depot, Inc. operates as a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services. It serves large and small pharmaceutical companies, government institutes, biotechnology companies, academic researchers and citizen scientists. The company was founded by Christopher L. Petersen, Andrew B. Martin, and Kevin D. Lustig in 2007 and is headquartered in Solana Beach, CA. | Commercial Services |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Miscellaneous |
Presidio Partners
 Presidio Partners Investment ManagersFinance Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California. | Finance |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Lawrence Berkeley National Laboratory
 Lawrence Berkeley National Laboratory Miscellaneous Commercial ServicesCommercial Services Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA. | Commercial Services |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Commercial Services |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Commercial Services |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Synchronicity Pharma, Inc.
 Synchronicity Pharma, Inc. Pharmaceuticals: OtherHealth Technology Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA. | Health Technology |
